Atlanta, Georgia 2021-06-14 09:22:00 –
Vaccine maker Nova Bucks said Monday that its COVID-19 shot was highly effective against the disease, protected from mutants in extensive studies in the United States and Mexico, and coveted by developing countries. Dose stated that it may sometimes provide the world with yet another weapon against the virus.
The two-shot vaccine was about 90% effective overall, and preliminary data showed that it was safe, said an American biotechnology company. It will make the vaccine about the same as Pfizer or Moderna.
Demand for COVID-19 shots in the United States has declined dramatically, and the country has exceeded enough to go around, but the need for more vaccines around the world remains important. Novavax vaccines, which are easy to store and transport, are expected to play an important role in facilitating vaccine supply in developing countries.
But the help is still months away. The company plans to seek approval for shots in the United States, Europe, etc. by the end of September, and says it will be able to generate up to 100 million doses per month by then.
“Many of our first doses … go to low- and middle-income countries, and that was our first goal,” said Novavax CEO Stanley Elk.
More than half of the US population is vaccinated at least once, but less than 1% of people in developing countries are vaccinated once. Data of our world..
Pfizer, Modana, Johnson & Johnson vaccines have already been approved for use in the United States and Europe. Europe also uses the AstraZeneca formula.
About 30,000 people over the age of 18 participated in the Novavax survey. Two-thirds received two vaccinations every three weeks and the rest received dummy shots.
There were 77 cases of COVID-19 — 14 in the vaccinated group and the rest volunteers who received dummy shots. None of the vaccine groups had moderate or severe illness compared to 14 in the placebo group.
The vaccine was equally effective against several variants, including the first detected in the United Kingdom, which predominates in the United States, and in high-risk populations, including the elderly and other people with health problems.
Side effects were mostly mild — tenderness and pain at the injection site. There were no reports of abnormal blood clots or heart problems, Elk said.
Novavax will report the results in a news release and publish them in medical journals scrutinized by independent experts. The company, based in Gaithersburg, Maryland, has previously published findings from small studies in the United Kingdom and South Africa.
The COVID-19 vaccine recognizes the coronavirus, especially the peplomer that covers it, and trains the body to prepare to fight the virus. The Novavax vaccine is made from a laboratory-grown copy of the protein. This is unlike some of the other vaccines in widespread use today. It contains genetic instructions for the body to make its own pepomer.
The Novavax vaccine can be stored in a standard refrigerator for easy distribution.
Novavax previously announced a production delay due to a shortage of supplies. The company currently expects to reach 100 million monthly production by the end of September and 150 million monthly production by December.
The company promises 110 million doses to the United States and 1.1 billion doses to developing countries next year.
In May, Gavi, a vaccine alliance that is the leader of a UN-sponsored COVAX project that provides shots to poor countries, announced that it had signed a contract to purchase 350 million Novavax prescriptions. COVAX faces a serious shortage of vaccines after India’s largest supplier stopped exporting until the end of the year.
Novavax has been working on vaccine development for over 30 years, but has not brought the vaccine to market. Its coronavirus vaccine work is partially funded by the US Government.
Dr. Peter English, a former British Medical Association vaccine expert, called the Novabax results “great news.” According to English, the production of vaccines is complicated, so it is important to give as many injections as possible.
“Small defects in a production plant can cause production to stop for days or weeks,” he said in a statement. “The more manufacturers that make vaccines, the more likely they are to get the vaccine.”
He said the encouraging news is that Novavax can adapt the vaccine to variants that may be of concern in the future if needed.
Follow Linda A. Johnson on Twitter. LindaJ—onPharma
AP Medical Writer Maria Cheng contributed to this report.
The Associated Press’s Department of Health Sciences is supported by the Department of Science Education at the Howard Hughes Medical Institute. AP is solely responsible for all content.
Copyright 2021 AP communication. all rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Novavax: Large study finds COVID-19 shot about 90% effective | News Source link Novavax: Large study finds COVID-19 shot about 90% effective | News